Veterinary Compounding Under the New FDA Guidance

The U.S. Food and Drug Administration's Guidance for Industry #256, Compounding Animal Drugs from Bulk Drug Substances, finalized in April 2022, sets out when FDA will not pursue enforcement against pharmacies and veterinarians that compound animal drugs from bulk substances instead of an FDA-approved product. The guidance draws a hard line around office stock, the compounded inventory a clinic keeps on hand without a patient-specific prescription. A pharmacy that fills office stock orders outside that lane, or cannot document the medical rationale FDA expects, risks an FDA warning letter and a parallel inquiry from the state board that licenses it.

What GFI #256 Actually Covers

GFI #256 applies only to compounding from bulk drug substances, active ingredients not yet formulated into any FDA-approved, conditionally approved, or indexed animal drug. It does not reach compounding from an already-approved product, crushing a tablet into a flavored liquid or combining two injectables in a syringe, which Congress separately authorized as extralabel use under the Animal Medicinal Drug Use Clarification Act and 21 CFR 530. Within its narrower scope, GFI #256 covers four situations: patient-specific prescriptions for nonfood-producing animals, office stock for nonfood-producing animals, antidotes for food-producing animals, and sedatives or anesthetics for free-ranging wildlife. Drugs compounded from bulk substances are not made under cGMP conditions and have not been reviewed by FDA, so they remain unapproved under the FD&C Act even where FDA elects not to act.

Office Stock Is the Narrowest Lane in the Guidance

Office stock, by FDA's own definition, is compounded medication a veterinarian keeps on hand without a prescription tied to a specific animal. Under GFI #256, a bulk drug substance may go into office stock only when it appears on FDA's List of Bulk Drug Substances for Compounding Office Stock Drugs, or the nominated list under review, and only when the drug is urgently necessary to prevent animal suffering or death in circumstances that leave no time to wait for a patient-specific compound. Office stock filled outside that use case sits at the top of FDA's enforcement priorities, alongside compounded copies of approved products and anything for a food-producing animal. The pharmacist or veterinarian who compounds the drug also carries a 15-day duty to report adverse events or product defects to FDA once the problem is known.

Where State Veterinary and Pharmacy Boards Come In

FDA generally leaves day-to-day inspection of a compounding pharmacy's drug quality to the state board that issued its license, a division of labor the Drug Quality and Security Act's Section 105 formalizes through routine communication between FDA and state boards of pharmacy. GFI #256 does not disturb that arrangement. A veterinarian's own in-office compounding and clinic office stock separately fall under the state veterinary medical board's authority over veterinary practice, distinct from any pharmacy license. A single office stock order outside GFI #256's enforcement-discretion criteria can open three tracks at once: an FDA warning letter, a state pharmacy board complaint, and a state veterinary board inquiry into the prescribing veterinarian, each on its own timeline and standard of proof.

Documentation That Holds Up at Inspection

When a compounded drug is a copy of an approved product, meaning the same active ingredient, route of administration, and an easily substitutable strength, GFI #256 requires the veterinarian's medical rationale documenting the clinical difference for that patient, retained with the prescription or the medical record. Pharmacies compounding sterile or hazardous veterinary preparations should hold themselves to USP 797/800 standards even though GFI #256 does not independently impose them, and every batch needs a beyond-use date tied to actual stability data. None of this substitutes for confirming, before the batch is made, that the bulk substance is on FDA's current list, and pharmacies serving both human 503A/503B lines and a veterinary practice should not assume one framework's recordkeeping satisfies the other.

An animal drug compounding inspection follows the same pattern as any FDA compounding inspection, including the narrow response window covered in FDA Form 483 Observations: The 15-Day Response and the downstream stakes described in FDA Warning Letters to Compounders: The Response That Closes the File.

Office stock compounded from a bulk drug substance is lawful only when that specific substance is on FDA's current list and the situation is urgent enough that there is no time to wait for a patient-specific prescription.

Why Early Legal Counsel Is Critical

It is critical that compounding pharmacies and veterinary practices promptly retain experienced healthcare defense counsel upon receiving an FDA inspection notice, a Form 483, a warning letter, or a state board inquiry tied to animal drug compounding. Early legal intervention can protect the pharmacy's rights, shape the response to FDA's observations, avoid inadvertent admissions, preserve relevant defenses, and allow counsel to communicate with investigators and state board staff on the pharmacy's behalf. Delaying legal representation can significantly affect the outcome of a matter and expose the pharmacy to unnecessary risk.

How Health Law Alliance Can Help

Health Law Alliance represents compounding pharmacies and veterinary practices through FDA inspections, warning letter responses, and state board proceedings tied to animal drug compounding under GFI #256. If your pharmacy has received an inspection notice, a Form 483, or a state veterinary or pharmacy board complaint involving office stock, our compounding pharmacy attorneys can review the record and shape the response before the matter escalates. Contact us today for a free consultation.